DK0794794T3 - Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler - Google Patents

Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler

Info

Publication number: DK0794794T3
Authority: DK; Denmark
Prior art keywords: agent; oral; target; bioavailability; enhancing
Prior art date: 1995-10-26

Application number

DK96943268T

Other languages

English (en)

Inventor

Sami Selim

Samuel Broder

Kenneth L Duchin

Original Assignee

Ivax Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-24

Publication date

2006-04-18

1996-02-29 Priority claimed from US08/608,776 external-priority patent/US5968972A/en

1996-10-24 Application filed by Ivax Research Inc filed Critical Ivax Research Inc

2006-04-18 Application granted granted Critical

2006-04-18 Publication of DK0794794T3 publication Critical patent/DK0794794T3/da

Links

230000002708 enhancing effect Effects 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 12
239000002246 antineoplastic agent Substances 0.000 abstract 2
238000011260 co-administration Methods 0.000 abstract 2
239000006186 oral dosage form Substances 0.000 abstract 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 abstract 1
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
108010019594 cyclosporin D Proteins 0.000 abstract 1
108010019252 cyclosporin F Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
229960004125 ketoconazole Drugs 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK96943268T 1995-10-26 1996-10-24 Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler DK0794794T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US707195P	1995-10-26	1995-10-26
US08/608,776 US5968972A (en)	1995-10-26	1996-02-29	Method for increasing the oral bioactivity of pharmaceutical agents
US08/733,142 US6245805B1 (en)	1995-10-26	1996-10-16	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (1)

Publication Number	Publication Date
DK0794794T3 true DK0794794T3 (da)	2006-04-18

Family

ID=27358262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96943268T DK0794794T3 (da)	1995-10-26	1996-10-24	Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler

Country Status (21)

Country	Link
US (6)	US6245805B1 (da)
EP (1)	EP0794794B1 (da)
JP (1)	JP3361102B2 (da)
CN (2)	CN100335123C (da)
AT (1)	ATE311903T1 (da)
AU (1)	AU698142B2 (da)
BR (1)	BR9607066A (da)
CA (1)	CA2205534A1 (da)
CZ (1)	CZ202897A3 (da)
DE (2)	DE794794T1 (da)
DK (1)	DK0794794T3 (da)
ES (1)	ES2109899T3 (da)
HU (1)	HUP9900457A3 (da)
IL (1)	IL121160A0 (da)
MX (1)	MX9704629A (da)
NO (1)	NO321091B1 (da)
NZ (1)	NZ324801A (da)
PL (2)	PL188281B1 (da)
RU (1)	RU2217135C2 (da)
SK (1)	SK85997A3 (da)
WO (1)	WO1997015269A2 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) *	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998053811A1 (en) *	1997-05-27	1998-12-03	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9718903D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999017760A2 (en) *	1997-10-02	1999-04-15	Microcide Pharmaceuticals, Inc.	Fungal or mammalian cell efflux pump inhibitors for enhancing susceptibility of the cell to a drug
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
EP1091745B1 (en) *	1998-06-29	2008-10-01	Children's Hospital Of Los Angeles	Treatment of hyperproliferative disorders
AU4955200A (en)	1999-05-17	2000-12-05	Cancer Research Ventures Limited	A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
RU2236226C2 (ru) *	1999-06-18	2004-09-20	Бейкер Нортон Фармасьютикалз, Инк.	Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
EP1479382A1 (en) *	1999-06-18	2004-11-24	IVAX Research, Inc.	Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
GB9920548D0 (en) *	1999-08-31	1999-11-03	Rhone Poulenc Rorer Sa	Treatment of hepatocellular carcinoma
US20020147197A1 (en) *	1999-10-08	2002-10-10	Newman Michael J.	Methods and compositions for enhancing pharmaceutical treatments
MXPA02004164A (es) *	1999-10-27	2002-10-17	Baker Norton Pharma	Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
US6638973B2 (en) *	2000-02-02	2003-10-28	Fsu Research Foundation, Inc.	Taxane formulations
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
EP1260233A1 (en) *	2000-03-02	2002-11-27	Hisamitsu Pharmaceutical Co. Inc.	P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
US6362217B2 (en)	2000-03-17	2002-03-26	Bristol-Myers Squibb Company	Taxane anticancer agents
LT2762140T (lt) *	2001-02-19	2017-06-26	Novartis Ag	Solidinių smegenų navikų gydymas rapamicino dariniu
US20030144312A1 (en) *	2001-10-30	2003-07-31	Schoenhard Grant L.	Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003041128A2 (en) *	2001-11-07	2003-05-15	Pharmacia Corporation	Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
EP1465618A2 (en) *	2001-12-20	2004-10-13	Bristol-Myers Squibb Company	Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
JP2006514698A (ja) *	2002-10-30	2006-05-11	スフェリックス，インコーポレイテッド	ナノ粒子生物活性物質
US20050113324A1 (en) *	2003-01-15	2005-05-26	Bondarev Igor E.	Modulation of line-1 reverse transcriptase
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
PE20060416A1 (es) *	2004-08-03	2006-06-09	Novartis Ag	Composicion de inhibidores de renina e inhibidores de proteinas de efusion
RU2359700C2 (ru) *	2004-10-26	2009-06-27	Фарма Мар С.А., Сосьедад Униперсональ	Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
CN101080224B (zh) *	2004-11-16	2011-03-30	利默里克神经科学股份有限公司	治疗疼痛的组合物及其应用
US20070087977A1 (en) *	2004-11-16	2007-04-19	Wendye Robbins	Methods and compositions for treating pain
EP3103468B1 (en) *	2005-10-14	2020-07-15	Allergan, Inc.	Prevention of drug-associated keratoconjunctivitis with a cyclosporin
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
JP2010530872A (ja) *	2007-06-22	2010-09-16	サイドース・エルエルシー	Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤
US20090111736A1 (en) *	2007-10-29	2009-04-30	Sri International	Orally-Absorbed Solid Dose Formulation for Vancomycin
CN101559059B (zh) *	2008-04-16	2012-12-05	北京万全阳光医学技术有限公司	一种含有盐酸阿米洛利的药物组合物及其制备方法
US20090318561A1 (en) *	2008-06-23	2009-12-24	Mutual Pharmaceutical Company, Inc.	Colchicine products, method of manufacture, and methods of use
US20110207660A1 (en) *	2008-08-07	2011-08-25	Schering Corporation	Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US7820681B1 (en) *	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
US20110046228A1 (en) *	2009-08-20	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for administration of colchicine with grapefruit juice
US8912228B2 (en)	2009-10-19	2014-12-16	Scidose Llc	Docetaxel formulations with lipoic acid
US8541465B2 (en) *	2009-10-19	2013-09-24	Scidose, Llc	Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) *	2009-10-19	2011-04-21	Scidose Llc	Solubilized formulation of docetaxel
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
JP5824511B2 (ja)	2010-05-03	2015-11-25	テイコクファーマユーエスエーインコーポレーテッド	非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
US20120295932A1 (en) *	2011-05-17	2012-11-22	Western Connecticut Health Network, Inc.	Method for the treatment of cancer
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TWI715636B (zh)	2015-09-30	2021-01-11	香港商慧源香港創新有限公司	口服紫杉烷組合物及方法
CN107843966B (zh)	2016-09-18	2021-05-04	中芯国际集成电路制造(上海)有限公司	用于装配微透镜阵列组件的方法和系统
CN106822085B (zh) *	2016-12-17	2020-03-17	浙江省人民医院	表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途
TWI833710B (zh)	2017-10-06	2024-03-01	香港商慧源香港創新有限公司	高單位含量口服型紫杉烷組合物及方法
CN112351779A (zh) *	2018-04-13	2021-02-09	慧源医疗有限公司	用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合
US20230149377A1 (en) *	2018-11-21	2023-05-18	Elevar Therapeutics, Inc.	Pharmaceutical methods

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118493A (en)	1986-05-02	1992-06-02	Brigham And Women's Hospital	Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
ES2059558T3 (es)	1987-06-17	1994-11-16	Sandoz Ag	Ciclosporins y su uso como productos farmaceuticos.
CA1340821C (en) *	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2525478B2 (ja)	1989-03-01	1996-08-21	帝人株式会社	安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US4960790A (en) *	1989-03-09	1990-10-02	University Of Kansas	Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5114951A (en)	1989-04-11	1992-05-19	Burroughs Wellcome Company	Agents for combating multiple drug resistance
US5208238A (en)	1989-06-19	1993-05-04	Burroughs Wellcome Company	Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914061D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914040D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8926715D0 (en)	1989-11-28	1990-01-17	Haessle Ab	Improvements relating to the administration of pharmaceutical agents
DE69120430D1 (de)	1990-12-18	1996-07-25	Wellcome Found	Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SG45403A1 (en)	1991-01-11	1998-01-16	Glaxo Lab Sa	Acridine derivatives
US5166207A (en)	1991-06-17	1992-11-24	Neurotherapeutics, Inc.	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5750561A (en)	1991-07-08	1998-05-12	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
ES2224200T3 (es)	1992-11-27	2005-03-01	Mayne Pharma (Usa) Inc.	Composicion inyectable estable de paclitaxel.
FR2698543B1 (fr)	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
US5646176A (en)	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US5387685A (en)	1993-07-16	1995-02-07	American Cyanamid Co	MDR reversal agents
CA2129288C (en) *	1993-08-17	2000-05-16	Jerzy Golik	Phosphonooxymethyl esters of taxane derivatives
TW406020B (en) *	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
US5567592A (en)	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr)	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) *	1994-07-19	1997-04-01	Hemagen/Pfc	Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5681846A (en) *	1995-03-17	1997-10-28	Board Of Regents, The University Of Texas System	Extended stability formulations for paclitaxel
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) *	1995-06-07	1998-02-10	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
GB9514878D0 (en) *	1995-07-20	1995-09-20	Danbiosyst Uk	Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US5968972A (en) *	1995-10-26	1999-10-19	Baker Norton Pharmaceuticals, Inc.	Method for increasing the oral bioactivity of pharmaceutical agents
WO1997027855A1 (en)	1996-01-31	1997-08-07	Bristol-Myers Squibb Company	A method of making pharmaceutically active taxanes orally bioavailable
US5877205A (en) *	1996-06-28	1999-03-02	Board Of Regents, The University Of Texas System	Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) *	1998-03-10	2001-01-28	Napro Biotherapeutics Inc	Novel methods and compositions for delivery of taxanes
US6136846A (en) *	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel

1996
- 1996-10-16 US US08/733,142 patent/US6245805B1/en not_active Expired - Fee Related
- 1996-10-24 DE DE0794794T patent/DE794794T1/de active Pending
- 1996-10-24 BR BR9607066-8A patent/BR9607066A/pt not_active Application Discontinuation
- 1996-10-24 MX MX9704629A patent/MX9704629A/es not_active IP Right Cessation
- 1996-10-24 DE DE69636531T patent/DE69636531T2/de not_active Expired - Fee Related
- 1996-10-24 WO PCT/IB1996/001485 patent/WO1997015269A2/en not_active Ceased
- 1996-10-24 DK DK96943268T patent/DK0794794T3/da active
- 1996-10-24 ES ES96943268T patent/ES2109899T3/es not_active Expired - Lifetime
- 1996-10-24 AT AT96943268T patent/ATE311903T1/de not_active IP Right Cessation
- 1996-10-24 HU HU9900457A patent/HUP9900457A3/hu unknown
- 1996-10-24 CN CNB031458033A patent/CN100335123C/zh not_active Expired - Fee Related
- 1996-10-24 PL PL96321791A patent/PL188281B1/pl not_active IP Right Cessation
- 1996-10-24 RU RU97112888/14A patent/RU2217135C2/ru not_active IP Right Cessation
- 1996-10-24 NZ NZ324801A patent/NZ324801A/xx unknown
- 1996-10-24 IL IL12116096A patent/IL121160A0/xx unknown
- 1996-10-24 PL PL368566A patent/PL192544B1/pl unknown
- 1996-10-24 JP JP51644997A patent/JP3361102B2/ja not_active Expired - Fee Related
- 1996-10-24 EP EP96943268A patent/EP0794794B1/en not_active Expired - Lifetime
- 1996-10-24 CZ CZ972028A patent/CZ202897A3/cs unknown
- 1996-10-24 CN CN96191685A patent/CN1119146C/zh not_active Expired - Fee Related
- 1996-10-24 CA CA002205534A patent/CA2205534A1/en not_active Abandoned
- 1996-10-24 SK SK859-97A patent/SK85997A3/sk unknown
- 1996-10-24 AU AU12056/97A patent/AU698142B2/en not_active Ceased
1997
- 1997-06-25 NO NO19972968A patent/NO321091B1/no unknown
2001
- 2001-04-10 US US09/829,846 patent/US6610735B2/en not_active Expired - Fee Related
2002
- 2002-09-12 US US10/242,050 patent/US6818615B2/en not_active Expired - Fee Related
2004
- 2004-03-15 US US10/800,990 patent/US7041640B2/en not_active Expired - Fee Related
2005
- 2005-04-13 US US11/105,081 patent/US20050238634A1/en not_active Abandoned
2006
- 2006-08-14 US US11/503,607 patent/US20070060635A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070060635A1 (en)	2007-03-15
AU1205697A (en)	1997-05-15
MX9704629A (es)	1997-09-30
PL321791A1 (en)	1997-12-22
CN100335123C (zh)	2007-09-05
HUP9900457A2 (hu)	1999-06-28
US20040176439A1 (en)	2004-09-09
US6818615B2 (en)	2004-11-16
IL121160A0 (en)	1997-11-20
DE794794T1 (de)	1998-03-12
NZ324801A (en)	1999-05-28
NO972968L (no)	1997-07-23
NO321091B1 (no)	2006-03-13
CN1173817A (zh)	1998-02-18
ES2109899T3 (es)	2006-05-01
HUP9900457A3 (en)	2001-04-28
WO1997015269A2 (en)	1997-05-01
CN1119146C (zh)	2003-08-27
CA2205534A1 (en)	1997-05-01
WO1997015269A3 (en)	1997-07-31
JPH10509741A (ja)	1998-09-22
US20030069301A1 (en)	2003-04-10
US6610735B2 (en)	2003-08-26
HK1001960A1 (en)	1998-07-24
DE69636531D1 (de)	2006-10-19
CN1490048A (zh)	2004-04-21
EP0794794A1 (en)	1997-09-17
US20050238634A1 (en)	2005-10-27
AU698142B2 (en)	1998-10-22
NO972968D0 (no)	1997-06-25
US6245805B1 (en)	2001-06-12
ES2109899T1 (es)	1998-02-01
SK85997A3 (en)	1998-06-03
PL192544B1 (pl)	2006-11-30
PL188281B1 (pl)	2005-01-31
US20020058616A1 (en)	2002-05-16
EP0794794B1 (en)	2005-12-07
CZ202897A3 (cs)	1998-03-18
JP3361102B2 (ja)	2003-01-07
DE69636531T2 (de)	2006-12-07
US7041640B2 (en)	2006-05-09
EP0794794A4 (en)	2000-03-01
BR9607066A (pt)	2002-12-10
ATE311903T1 (de)	2005-12-15
RU2217135C2 (ru)	2003-11-27

Publication	Publication Date	Title
NO972968D0 (no)	1997-06-25	Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler
MXPA04000920A (es)	2004-04-02	Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BG101118A (en)	1998-04-30	Therapeutical compounds
ATE306266T1 (de)	2005-10-15	Verbesserte verabreichungstechnik für multiple medikamentengaben
BR0211794A (pt)	2004-11-03	Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
WO2005065069A3 (en)	2005-09-22	Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IT1245889B (it)	1994-10-25	Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
DE69906518D1 (de)	2003-05-08	Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
DE69940674D1 (de)	2009-05-14	Orale verabreichung von adenosin analogen
LU90266I2 (fr)	1998-10-01	Composition comprenant du losartan potassium et du hydrochlorothiazide ou leurs dérivés pharmaceutiquement acceptables (hyzaarÐ)
DE69713526D1 (de)	2002-07-25	Lösliche prodrugs von paclitaxel
CO5251419A1 (es)	2003-02-28	Composiciones nanoparticuladas de eplerenona
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
ATE292453T1 (de)	2005-04-15	Antivirale arznei
BG105173A (en)	2001-11-30	Novel salt form of pantoprazole
HUP9603237A2 (hu)	1998-01-28	(R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
DE122006000057I2 (de)	2009-11-05	Proteinhaltige arzneimittel
DE60215313D1 (de)	2006-11-23	Indolderivate und deren verwendung als gnrh antagonisten
ATE268174T1 (de)	2004-06-15	Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
RU2003125274A (ru)	2005-01-20	Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
ATE337016T1 (de)	2006-09-15	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
BR0017329A (pt)	2003-07-29	Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
DK1492539T3 (da)	2006-10-30	Statin-terapi til forögelse af kognitiv funktion
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel